La croissance diversifiée - ACHAT - OC 27,8£
Nous initions la couverture de la société HIKMA avec une recommandation à ACHAT et un objectif de cours de 27,8£ reflétant un potentiel de hausse de 20%. Nous voyons en l’acquisition de Roxane une diversification de son activité générique conduisant à une réallocation beaucoup plus homogène de ses activités. Avec « son track record » et des synergies visibles entre ses activités, nous pensons que les guidances de ventes et de synergies de coûts formulées par la société restent prudentes. Après une année 2016 de transition suite à cette intégration, cette Pharma de spécialité présente une croissance des BNA de +29% sur la période 2016-2019e lui permettant d’afficher un PEG de seulement 1x.Hikma Pharmaceuticals is a pharmaceutical company engaged in developing, manufacturing, and marketing a range of branded and non-branded generic pharmaceutical products across the U.S., the Middle East and North Africa, and Europe. Co.'s business segments are: Injectables, which sells specialized generic injectable products, including sterile liquid, powder, lyophilized and cytotoxic products; Generics, which sells non-injectable generic products that include amoxicillin, buprenorphine, butalbital, acetaminophen and caffeine, colchicine, and fluticasone; and Branded products, which sells branded generics and in-licensed products including Amoclan®, Blopress®, Omnicef®, Prograf® and Suprax®.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.